Jun 12, 2017 8:00am EDT Ensysce Biosciences Inc. Attending NIH Conference: Cutting Edge Science Meeting Series to End the Opioid Crisis: Development of Safe, Effective, Non-Addictive Pain Treatments
Apr 03, 2017 8:00am EDT Ensysce Biosciences Inc. Publishes Manuscript Describing the in Vitro Abuse Deterrence of Oxycodone Prodrug, PF614
Jan 02, 2017 1:12pm EST Ensysce Biosciences to present initial Phase 1 data on abuse deterrent opioid, PF614, at Biotech Showcase™ 2017.
Dec 01, 2016 2:00pm EST Ensysce Biosciences Inc. Initiates Phase 1 Clinical Trial to Study PF614, BIO-MD™ Prodrug of Oxycodone
Oct 25, 2016 8:00am EDT Ensysce Biosciences Inc. Speaking at 3rd Human Abuse Liability & Abuse-Deterrent Formulation Conference
Jul 07, 2015 6:54pm EDT Ensysce Biosciences Inc. Demonstrates Carbon Nanotube Delivery of RNA to PBMCs
Mar 06, 2014 2:25pm EST Ensysce Biosciences Inc. Receives Notice of Allowance for U.S. Patent for Delivery of siRNA
Sep 25, 2012 11:52am EDT Ensysce Biosciences Inc. Receives Small Business Grant from NIH to Optimize Single Walled Carbon Nanotube Formulation for Therapeutic Delivery of siRNA
Jun 06, 2012 10:35am EDT Ensysce Biosciences Inc. Completes Qualifying Financial Transaction Matching Emerging Technology Funds from the State of Texas
